摘要
目的评价贝伐单抗、卡培他滨、奥沙利铂联合应用治疗晚期胃癌的效果。方法对2015年2月—2017年7月在该院接受治疗的晚期胃癌患者,从中选择82例作为该次研究对象,奇偶数法随机分为两组,各组41例。参照组患者采用顺铂与多西他赛联合氟尿嘧啶治疗,试验组患者采用贝伐单抗、卡培他滨、奥沙利铂联合应用治疗。观察与比较两组临床指标患者近期疗效、生活质量以及不良反应发生率。结果治疗后,试验组CEA(19.74±5.18)mg/L、CA199 (192.73±21.47)mg/L、CA242 (37.83±3.49)mg/L低于参照组(2.83±5.09)mg/L、(273.57±21.34)mg/L、(65.87±8.73)mg/L,差异有统计学意义(t=4.158、4.025、4.382,P<0.05);试验组中位疾病进展时间(7.18±0.26)月、中位生存时间(12.54±2.18)月长于参照组(4.63±0.31)月、(7.93±2.07)月,差异有统计学意义(t=4.117、4.309,P<0.05);试验组客观有效率82.93%高于参照组70.73%,不良反应发生率4.88%低于参照组21.95%,差异有统计学意义(χ^2=6.732、7.014,P<0.05)。结论对晚期胃癌患者联合应用贝伐单抗、卡培他滨、奥沙利铂治疗可以明显降低患者体内血清肿瘤标志物浓度,能够提升患者生活质量,且治疗安全性更高,近期疗效更佳。
Objective To evaluate the effect of bevacizumab,capecitabine,and oxaliplatin in the treatment of advanced gastric cancer.Methods Eighty-two patients with advanced gastric cancer who were treated in the hospital from February 2015 to July 2017 were selected as the subjects of this study.The parity method was randomly divided into two groups,with 41 in each group.Patients in the reference group were treated with cisplatin and docetaxel in combination with fluorouracil.Patients in the test group were treated with bevacizumab,capecitabine,and oxaliplatin.Observe and compare the clinical efficacy,quality of life,and incidence of adverse reactions in two groups of patients with clinical indicators.Results After treatment,the CEA(19.74±5.18)mg/L,CA199(192.73±21.47)mg/L,and CA242(37.83±3.49)mg/L in the test group were lower than the reference group(32.83±5.09)mg/L,(273.57±21.34)mg/L,(65.87±8.73)mg/L,with statistical differences(t=4.158,4.025,4.382,P<0.05);the median disease progression time(7.18±0.26)month and median survival time(12.54±2.18)month in the experimental group were longer than the reference group(4.63±0.31)month,(7.93±2.07)month,with statistical differences(t=4.117,4.309,P<0.05);the objective effective rate in the test group was 82.93%higher than the reference group 70.73%,and the incidence of adverse reactions 4.88%was lower than the reference group 21.95%,with statistical differences(χ^2=6.732,7.014,P<0.05).Conclusion The combination of bevacizumab,capecitabine,and oxaliplatin in patients with advanced gastric cancer can significantly reduce the concentration of serum tumor markers in patients,improve the quality of life of patients,and have higher treatment safety and better short-term efficacy.
作者
司峻岭
SI Jun-ling(Department of Oncology,People's Hospital of Linyi County,Linyi,Shandong Province,251500 China)
出处
《系统医学》
2020年第8期71-73,共3页
Systems Medicine
关键词
胃癌
贝伐单抗
奥沙利铂
卡培他滨
效果
Gastric cancer
Bevacizumab
Oxaliplatin
Capecitabine
Effect
